Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
Prostate Cancer · 2011
DOI: 10.1155/2011/258689 ↗At a glance
Journal article in Prostate Cancer, 2011. Written by Filippo Francini and 14 co-authors. Institution: Department of Odontostomatology and Maxillo-Facial Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy. Cited 13 times so far (Crossref); 34 references. The full text is freely available (open access, CC BY 3.0).
Abstract (original language)
Background
The aim of this paper was to evaluate the activity and tolerability of docetaxel (D) and bevacizumab (Bev) in patients with metastatic castrate-resistant prostate cancer (CRPC) previously exposed to D.
Methods
Treatment consisted of D 30 mg/m 2 i.v. for four consecutive weekly administrations followed by a 2-week rest interval, in addition to Bev 5 mg/kg i.v. every 2 weeks.
Results
Forty-three patients were enrolled: a PSA response was observed in 27 patients (62.7%, 95% CI: 0.41 to 0.91), and a palliative response was achieved in 31 patients (72.1%, 95%CI: 0.48 to 1.02). After a median followup of 11.3 months, only five patients had died. The regimen was generally well tolerated.
Conclusion
Weekly D + biweekly Bev seems to be an effective and well-tolerated treatment option for patients with metastatic CRPC previously exposed to D-based chemotherapy.
Authors and institutions
- Department of Odontostomatology and Maxillo-Facial Surgery, University of Siena, Policlinico Le Scotte, Viale Bracci 11, 53100 Siena, Italy.
Cite
APA
Francini, F., Pascucci, A., Francini, E., Bargagli, G., Conca, R., Licchetta, A., Roviello, G., Martellucci, I., Chiriacò, G., Miano, S. T., Marzocca, G., Manganelli, A., Ponchietti, R., Savelli, V., & Petrioli, R. (2011). Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel. Prostate Cancer. https://doi.org/10.1155/2011/258689
Vancouver
Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, et al. Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel. Prostate Cancer. 2011. doi:10.1155/2011/258689
BibTeX
@article{Francini2011,
author = {Francini, Filippo and Pascucci, Alessandra and Francini, Edoardo and Bargagli, Gianluca and Conca, Raffaele and Licchetta, Antonella and Roviello, Giandomenico and Martellucci, Ignazio and Chiriacò, Giorgio and Miano, Salvatora Tindara and Marzocca, Giuseppe and Manganelli, Antonio and Ponchietti, Roberto and Savelli, Vinno and Petrioli, Roberto},
title = {Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel},
journal = {Prostate Cancer},
year = {2011},
doi = {10.1155/2011/258689}
}
EUVIMED